PAKOLA STEVE 4

What Happened
Steve Pakola, Chief Medical Officer of REGENXBIO, sold 15,309 shares on 2026-05-11. The filing reports a weighted average sale price of $11.02 per share for total proceeds of roughly $168,705. The sale was executed as an open-market transaction (reported as “S”).

Key Details

• Transaction date: 2026-05-11; Form 4 filed: 2026-05-13 (filed two days after the transaction).
• Shares sold: 15,309; weighted average price: $11.02; approximate proceeds: $168,705.
• Price range: $11.00 to $11.10 across multiple trades (per filing footnote). The reported $11.02 is the weighted average.
• Footnotes: F1 — transaction effected pursuant to a Rule 10b5-1 trading plan. F2 — executed in multiple trades; reporting person will provide full trade-level details on request.
• Shares owned after transaction: not specified in the provided excerpt of the Form 4.
• Timeliness: Form 4 was filed two days after the trade, which is within the typical 2-business-day filing window.

Context
The sale was made under a pre-established Rule 10b5-1 plan, which generally indicates the trades were pre-scheduled and limits how much the sale reveals about the insider’s current view of the company. Sales by insiders can be routine (e.g., for diversification or liquidity); purchases are typically more informative about insider sentiment.